IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas (NHL)
Sponsor: Iksuda Therapeutics Ltd.
This PHASE1 trial investigates B-cell Lymphoma and B-cell Non-Hodgkin Lymphoma and is currently actively recruiting participants. Iksuda Therapeutics Ltd. leads this study, which shows 10 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Nov 2025 — Present [monthly]
Recruiting PHASE1
-
Sep 2025 — Nov 2025 [monthly]
Recruiting PHASE1
-
Oct 2024 — Sep 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
▶ Show 5 earlier versions
-
Nov 2023 — Jul 2024 [monthly]
Recruiting PHASE1
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2023 — Oct 2023 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2023 — Jun 2023 [monthly]
Not Yet Recruiting PHASE1
-
Jun 2022 — Jan 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Iksuda Therapeutics Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia , Badalona, Spain , Baltimore, United States , Candiolo, Italy , Hobart, Australia , Madrid, Spain , Milan, Italy , Montreal, Canada , Perth, Australia , Salamanca, Spain and 1 more location